Fujifilm to invest $2bn in new US cell culture production site

pharmafile | January 7, 2021 | News story | |  Fujifilm Diosynth Biotechnologies 

Fujifilm has announced it is investing $2 billion to establish a new large-scale cell culture production site in the US.

The new facility, which will be operated by Fujifilm’s subsidiary Diosynth Biotechnologies, will offer large-scale cell culture manufacturing of bulk drug substance with eight 20,000L bioreactors, and with the potential to expand and add a further 24 20,000L bioreactors based on market demand.

In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labelling services. The new site will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025.

Fujifilm is actively investing to enhance and grow its end to end service offerings across all of its biopharmaceutical contract development and manufacturing business sites. In June, the company invested $928 million in Fujifilm Diosynth Biotechnologies’ Hillerød, Denmark, site to double its large-scale cell culture manufacturing capacity and add commercial scale drug product production capabilities.

Kenji Sukeno, president of Fujifilm, said: “The United States is the world’s biggest market for biopharmaceuticals. I am pleased that through this large investment in the US we are able to support the development and manufacturing of new drugs that can help fulfill unmet medical needs.

“Fujifilm will continue to promote human health and support the progress of the healthcare industry by using our cutting-edge technology and advanced facilities to provide a stable supply of high-quality biopharmaceuticals.”

Darcy Jimenez

Related Content

ABPI image

ABPI and BIA establish new manufacturing partnership

The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry …

NIBS image

Manufacturing facilities news in brief

New facilities, plant shutdowns and layoffs in the pharma manufacturing sector.

Latest content